REG - Uniphar PLC - Directorate Change

UnipharAnnouncement

17/12/2021 08:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211217:nRSQ9634Va&default-theme=true

RNS Number : 9634V  Uniphar PLC  17 December 2021

 

Directorate Changes

Dublin, London | 17 December 2021

Uniphar plc (the "Company") wishes to announce that Ger Penny will resign from
the Board with effect from 17 December 2021. Ger joined the Board as a
representative of the Sisk Family on the acquisition of Sisk Healthcare Group
in 2018 and resigns in line with the appointment rights granted in connection
with that acquisition.

The Company also wishes to announce that Padraic Dempsey, Executive Director,
will resign from the Board with effect from 17 December 2021. Padraic has
served on the Board for a four-year term and will continue in his role as
Chief Commercial Officer of the Group.

Maurice Pratt, Chairman of Uniphar plc, commented:

"On behalf of the Board, I would like to take this opportunity to thank Ger
for the support and commitment he has shown to the Board over the last three
years. Ger's experience and insights have been a great support to the Board
and we wish him every success with his future endeavours.

The Directors and I would also like to thank Padraic for his valuable
contributions to the Board over the past four years and we look forward to his
continuing success in his executive role.

Since IPO, the Board has been focused on transitioning Board composition to
meet the requirements of the UK Corporate Governance Code. The resignations
announced today will mean a majority of our Board members will be considered
independent, with the number of Executive Directors on the Board reducing from
three to two, further enhancing the balance between Executive and
Non-Executive representation on the Board."

Having regard to the current size and composition of the Board, the Board is
not currently considering any new appointments to the Board at this time.

 

--- ENDS ---

For further details contact:

 

 Uniphar                                        +353 (0) 1 428 7777

 Brian O'Shaughnessy
 Group Director of Corporate Development        investor.relations@Uniphar.ie (mailto:investor.relations@Uniphar.ie)

 Davy                                           +353 (0) 1 679 6363
 (Joint Broker, Nominated Adviser and Euronext

 Growth Adviser)

 Barry Murphy
 Niall Gilchrist

 Lauren O'Sullivan

 RBC Capital Markets (Joint Broker)             +44 (0) 20 7653 4000

 Jonathan Hardy
 Jamil Miah

 Priyal Soni

 Stifel Nicolaus Europe Limited (Joint Broker)  +44 (0) 20 7710 7600

 Matt Blawat
 Ben Maddison
 Francis North

 Q4 PR                                          +353 (0) 1 475 1444 or
 (Public Relations Adviser to Uniphar)          +353 87 235 6461

 Iarla Mongey

 

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, Uniphar is an international diversified
healthcare services business servicing the requirements of more than 200
multinational pharmaceutical and medical technology manufacturers across three
divisions - Commercial & Clinical, Product Access and Supply Chain &
Retail. With a workforce of more than 3,200, the Group is active in Ireland,
the UK, the Benelux, the Nordics, Germany and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth and
profitability.

 

Commercial & Clinical

In Commercial & Clinical the Group provides sales, marketing &
distribution solutions to multinational pharmaceutical and medical device
manufacturers on an outsourced basis. Active in Ireland, the UK, Benelux, the
Nordics, Germany and the US, the Group is growing with its clients to provide
pan-European solutions. Uniphar has built a fully integrated multi-channel
solution that is supported by our highly experienced and clinically trained
teams leveraging our digital technology and insights which allows us to
deliver consistently exceptional outcomes for our clients.

 

Product Access

In Product Access the Group is growing two distinct service offerings: 1) "On
Demand Access", which are pharmacy led solutions for sourcing and supplying
unlicensed medicines to meet the needs of both retail and hospital
pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions
for controlling the release of speciality medicines for specifically approved
patient populations in agreed markets. The Group currently delivers product
access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with over a 50% market
share in the wholesale/hospital market, supported by a network of c.360 owned,
franchised and symbol group pharmacies. The business supports the diverse
customer base through the provision of strong service levels coupled with
innovative commercial initiatives. Supply Chain & Retail is an Irish only
business for the Group, although the manufacturer relationships and
infrastructure are utilised for the benefit of the growth divisions,
Commercial & Clinical and Product Access.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEANAKFSEFFFA